| | |
| Clinical data | |
|---|---|
| Other names | MDMPEA; 1,3-Benzodioxolyl-N-methyl-5-ethanamine; 3,4-Methylenedioxy-N-methyl-2-phenylethylamine; Norlobivine; METHYL-H; METHYL-MDPEA; N-Me-MDPEA |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H13NO2 |
| Molar mass | 179.219 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Homarylamine (INN ), [1] also known as 3,4-methylenedioxy-N-methylphenethylamine (MDMPEA) or as METHYL-H, is a chemical compound of the phenethylamine and methylenedioxyphenethylamine (MDxx) family. [2] It is the N-methyl derivative of homopiperonylamine (methylenedioxyphenethylamine; MDPEA; H). [2] The drug was patented by Merck & Co. in 1956 [3] and studied as an antitussive (cough suppressant) in 1961. [2] [4] It is a schedule I drug in the United States as a positional isomer of 3,4-methylenedioxyamphetamine (MDA).
Homarylamine was briefly mentioned by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). [2] According to Shulgin, homarylamine has been reported to be active as an antitussive (cough suppressant) at a dose of 30 mg. [2] No central effects were described as this dose. [2] Shulgin tried this dose and experienced a little tightness of facial muscles, but no mental effects whatsoever. [2]
Reaction of homarylamine with formaldehyde gives hydrastinine.[ citation needed ]
A practical application of homarylamine is in the synthesis of Roemerin . [5]
Analogues of homarylamine include homopiperonylamine (MDPEA), lobivine (MDDMPEA), lophophine (MMDPEA), MDA, MDMA, hydrastine, and hydrastinine, among others. [2]